详情页

当前位置：首页 > 详情页

The correlation between adverse events and survival benefits of donafenib in the first-line treatment of advanced hepatocellular carcinoma

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：

机构： [1]Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu,China [2]PLA Cancer Centre of Nanjing, Jinling Hospital, Nanjing, China [3]Department ofMedical Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China [4]Department of Hepatobiliary Surgery, The First Affiliated Hospital of ChongqingMedical University, Chongqing, China [5]Department of Oncology, The First AffiliatedHospital of Zhengzhou University, Zhengzhou, China [6]Department of Radiotherapy,The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China [7]Department ofOncology, The First Affiliated Hospital of Soochow University, Suzhou, China [8]Department of Medical Oncology, The Fourth Hospital of Hebei Medical University,Shijiazhuang, China [9]Department of Oncology, Zhujiang Hospital of Southern MedicalUniversity, Guangzhou, China [10]Department of Infection and Liver Diseases, The FirstAffiliated Hospital of Wenzhou Medical University, Wenzhou, China [11]Department ofInfectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University,Hangzhou, China [12]Department of Intervention Therapy, Cancer Hospital ofShantou University Medical College, Shantou, China [13]Department of Oncology, TheFirst People’s Hospital of Changzhou, Changzhou, China [14]Suzhou Zelgen BiopharmaceuticalsCo., Ltd., Suzhou, China

出处：

DOI：

ISSN：

基金：

语种：

WOS：

中科院分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2021]版：

Q1 ONCOLOGY

最新[2024]版：

Q1 ONCOLOGY

影响因子： 65.4 最新[2024版] 46.8 最新五年平均 51.769 出版当年[2021版] 29.61 出版当年五年平均 32.976 出版前一年[2020版] 50.5 出版后一年[2022版]

第一作者：

第一作者机构： [1]Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu,China

推荐引用方式(GB/T 7714)：

APA：

MLA：